Dr. Salani Discusses Potential Treatment Modalities in Cervical Cancer

Ritu Salani, MD
Published: Wednesday, Nov 20, 2019




Ritu Salani, MD, gynecologic oncologist, associate professor, Department of Obstetrics and Gynecology, director, Gynecologic Oncology Fellowship Program, The Ohio State University Wexner Medical Center, discusses the potential of targeted therapy and immunotherapy in cervical cancer.
 
Recurrent cervical cancer is often associated with a poor prognosis, explains Salani. Patients with recurrent disease tend to be younger, and the toxicities of current treatments can be difficult to tolerate.
 
With targeted therapy and immunotherapy, there is an opportunity to provide patients with minimally toxic treatments that improve outcomes, says Salani. Additionally, these modalities could play a role in the maintenance setting following induction chemotherapy.  
 
SELECTED
LANGUAGE



Ritu Salani, MD, gynecologic oncologist, associate professor, Department of Obstetrics and Gynecology, director, Gynecologic Oncology Fellowship Program, The Ohio State University Wexner Medical Center, discusses the potential of targeted therapy and immunotherapy in cervical cancer.
 
Recurrent cervical cancer is often associated with a poor prognosis, explains Salani. Patients with recurrent disease tend to be younger, and the toxicities of current treatments can be difficult to tolerate.
 
With targeted therapy and immunotherapy, there is an opportunity to provide patients with minimally toxic treatments that improve outcomes, says Salani. Additionally, these modalities could play a role in the maintenance setting following induction chemotherapy.  
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x